---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000068"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-09-21T20:10:47+00:00"
generated_at: "2026-09-21T20:12:24.000907+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Brad Campbell named Travere CEO, succeeding Eric Dube effective Dec 1

## Summary
- Eric Dube steps down as Travere President/CEO and Director effective Dec 1, 2026, remaining Executive Advisor until Feb 15, 2027.
- Bradley Campbell (ex-CEO of Amicus until its Apr 2026 BioMarin acquisition) starts as President/CEO and Director on Dec 1, 2026.
- Campbell receives $1.0M base salary, 85% target bonus, $500k expense payment, and ~$16.5M initial equity (option + RSUs); ~$3.75M performance RSU in 2027.
- Dube keeps salary through Feb 2027, eligible for 75% 2026 bonus, but no 2027 bonus or new equity; performance RSUs cease vesting at separation.

## SEC filing metadata
- accession: 0001438533-26-000068
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-09-21T20:10:47+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/tvtx-20260921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000068
- JSON: https://secwatch.observer/filing/0001438533-26-000068.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000068.txt

## Key facts
- Executive change
  Bradley L. Campbell was appointed as President and Chief Executive Officer at Travere Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm
- Executive change
  Eric Dube was appointed as Executive Advisor at Travere Therapeutics, Inc..
  - Action: agreed to continue as
  - Role: Executive Advisor
  source text: As discussed in greater detail below, Dr. Dube has agreed to continue with the Company as Executive Advisor through February 15, 2027, to facilitate a smooth transition of responsibilities and has agreed to serve as Consultant to the Chief Executive Officer for a period following the employment transition.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm
- Executive change
  Bradley L. Campbell was appointed as Member of the Board of Directors at Travere Therapeutics, Inc..
  - Action: appointed
  - Role: Member of the Board of Directors
  source text: Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.